Natera, Inc. (NASDAQ:NTRA) Shares Sold by Bank of Hawaii

Bank of Hawaii lessened its stake in Natera, Inc. (NASDAQ:NTRA) by 8.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 32,032 shares of the medical research company’s stock after selling 2,822 shares during the period. Bank of Hawaii’s holdings in Natera were worth $5,071,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Blue Trust Inc. lifted its position in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the last quarter. Versant Capital Management Inc increased its stake in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares during the period. EverSource Wealth Advisors LLC increased its stake in Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock valued at $52,000 after purchasing an additional 261 shares during the period. Principal Securities Inc. increased its stake in Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 59 shares during the period. Finally, Steward Partners Investment Advisory LLC increased its stake in Natera by 1,328.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock valued at $57,000 after purchasing an additional 332 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Trading Up 14.9 %

NASDAQ NTRA opened at $151.97 on Thursday. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a twelve month low of $83.13 and a twelve month high of $183.00. The firm has a market capitalization of $20.54 billion, a PE ratio of -86.35 and a beta of 1.80. The stock’s 50 day moving average is $153.85 and its 200 day moving average is $151.75.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. The firm had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Transactions at Natera

In other Natera news, insider John Fesko sold 663 shares of Natera stock in a transaction dated Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the transaction, the insider now owns 156,044 shares in the company, valued at approximately $27,739,941.88. This trade represents a 0.42 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gail Boxer Marcus sold 4,000 shares of Natera stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $147.69, for a total value of $590,760.00. Following the completion of the transaction, the director now owns 9,704 shares of the company’s stock, valued at approximately $1,433,183.76. This represents a 29.19 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 325,922 shares of company stock worth $51,603,664. 7.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

NTRA has been the topic of a number of recent analyst reports. BTIG Research reiterated a “buy” rating on shares of Natera in a research note on Friday, February 28th. JPMorgan Chase & Co. upped their price target on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Robert W. Baird upped their price target on shares of Natera from $183.00 to $188.00 and gave the company an “outperform” rating in a report on Friday, February 28th. The Goldman Sachs Group upped their price objective on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Finally, Barclays began coverage on shares of Natera in a report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 target price on the stock. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average price target of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.